Shares of Puma Biotechnology, Inc. PBYI have plunged 38.4% in the past three months compared with the industry’s decline of 4.8%. The company’s sole marketed product, Nerlynx (neratinib), is approved ...
Source LinkShares of Puma Biotechnology, Inc. PBYI have plunged 38.4% in the past three months compared with the industry’s decline of 4.8%. The company’s sole marketed product, Nerlynx (neratinib), is approved ...
Source Link
Comments